HCW Biologics (HCWB) Stock Price, News & Analysis

Company Overview

HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression.

HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression. The company has investigated its candidates in oncology and other diseases involving chronic inflammation.

HCW Biologics is headquartered in Miramar, Florida, and conducts its work through research, preclinical and clinical development programs. As a development-stage biotechnology company, its products remain investigational and are subject to clinical testing and regulatory review before they can be marketed.

Key Stats

• Today's Range: $0.77 to $0.86
• 50-Day Range: $0.77 to $2.94
• 52-Week Range: $0.76 to $23.94
• Volume: 22,314 shs
• Average Volume: 51,048 shs
• Market Capitalization: $1.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Hold

HCW Biologics Stock Analysis - MarketRank™

HCW Biologics scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

HCW Biologics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

HCW Biologics has a consensus price target of $30.00, representing about 3,780.5% upside from its current price of $0.77.

Amount of Analyst Coverage

HCW Biologics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of HCW Biologics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HCW Biologics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HCW Biologics has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.42% of the float of HCW Biologics has been sold short.

Short Interest Ratio / Days to Cover

HCW Biologics has a short interest ratio ("days to cover") of 0.86, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HCW Biologics has recently increased by 30.71%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HCW Biologics does not currently pay a dividend.

Dividend Growth

HCW Biologics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.89

News Sentiment

HCW Biologics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for HCW Biologics this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for HCWB on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HCW Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.10% of the stock of HCW Biologics is held by insiders.

Percentage Held by Institutions

2.96% of the stock of HCW Biologics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/15/2026
• Next Earnings (Estimated): 11/16/2026
• EGM 2026: 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:HCWB
• CIK: 1828673
• Web: www.hcwbiologics.com
• Phone: 954-842-2024
• Fax: 954-842-2037
• Employees: 35
• Year Founded: 2018

Price Target and Rating

• Average Price Target for HCW Biologics: $30.00
• High Price Target: $30.00
• Low Price Target: $30.00
• Potential Upside/Downside: +3,780.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($27.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.96 million
• Net Margins: -83.03%
• Pretax Margin: -78.12%
• Return on Equity: -262.33%
• Return on Assets: -34.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.06
• Quick Ratio: 0.06

Sales & Book Value

• Annual Sales: $50 thousand
• Price / Sales: 34.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.06 per share
• Price / Book: 0.15

Miscellaneous

• Outstanding Shares: 2,240,000
• Free Float: 2,033,000
• Market Cap: $1.73 million
• Optionable: Not Optionable
• Beta: 2.31